Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 18, 2024, specifically the Company's Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes regarding director elections, compensation plans, and auditor ratification.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Voting Results
As of the record date (April 23, 2024), 83,133,341 shares were outstanding, with 78,535,662 shares represented at the meeting. The following proposals were voted upon:
- Proposal 1 (Election of Class II Directors): Stockholders elected Deborah Dunsire, M.D., Michael Narachi, and Corsee Sanders, Ph.D. All nominees received majority support.
- Proposal 2 (Amended and Restated 2023 Incentive Plan): Stockholders approved the plan. However, the vote was split, with 51,942,752 votes for and 22,299,718 votes against.
- Proposal 3 (Ratification of Auditor): Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2024, with 77,155,452 votes for.
- Proposal 4 (Advisory Vote on Executive Compensation): Stockholders voted in favor of the "say-on-pay" resolution, with 54,803,351 votes for and 19,320,182 votes against.
Guidance, Outlook, and Risks
The filing contains no management commentary on future guidance, outlook, or specific business risks. It references the 2024 Proxy Statement for detailed descriptions of the Incentive Plan and executive compensation.
Key Facts for Investor Verification
- Verify the specific terms of the Amended and Restated 2023 Incentive Plan (Exhibit 10.1) given the significant number of votes cast against it.
- Review the 2024 Proxy Statement for detailed context on the executive compensation package approved in Proposal 4.
- Confirm the tenure of the newly elected Class II directors, which extends until the 2027 Annual Meeting.
- Note that this filing does not contain updated financial results; refer to the most recent 10-Q or 10-K for financial health metrics.